Cambiar Aggressive Value ETF

34.25

0.0000

Volume:7.00

Turnover:240.62

Market Cap:66.34M

PE:- -

High:34.25

Open:34.25

Low:34.25

Close:34.25

52wk High:34.28

52wk Low:26.45

Shares:1.94M

Float Shares:1.94M

Volume Ratio:0.04

T/O Rate:0.00%

Dividend:0.57

Dividend Rate:1.67%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Camurus Receives CHMP Recommendation for Potential Drug to Treat Rare Disease Caused by Pituitary Gland Tumor

MT Newswires Live

·

Apr 25, 2025

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CAMX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CAMX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CAMX\",,,,,undefined,":{"symbol":"CAMX","market":"US","secType":"STK","nameCN":"Cambiar Aggressive Value ETF","latestPrice":34.25,"timestamp":1770908971788,"preClose":34.25,"halted":0,"volume":7,"delay":0,"changeRate":0,"floatShares":1936961,"shares":1936961,"eps":0,"marketStatus":"Trading","change":0,"latestTime":"02-12 12:47:45 EST","open":34.25,"high":34.25,"low":34.25,"amount":240.61919,"amplitude":0,"askPrice":33.94,"askSize":100,"bidPrice":33.56,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1770930000000},"marketStatusCode":2,"adr":0,"exchange":"ARCA","adjPreClose":34.25,"sharesOutstanding":1936961,"nav":34.29,"aum":66416908.25,"dividendRate":0.016709,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":34.25,"preClose":34.25,"latestTime":"16:10 EST","volume":6,"amount":205.5,"timestamp":1770844204805,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.041084},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CAMX\",,,,,undefined,":{"symbol":"CAMX","floatShares":1936961,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.041084,"shares":1936961,"dividePrice":0.5723,"high":34.25,"amplitude":0,"preClose":34.25,"low":34.25,"week52Low":26.45,"pbRate":"--","week52High":34.28,"institutionHeld":0,"latestPrice":34.25,"eps":0,"divideRate":0.016709,"volume":7,"delay":0,"ttmEps":0,"open":34.25,"prevYearClose":31.5145,"prevWeekClose":33.2386,"prevMonthClose":33.0024,"prevQuarterClose":31.5145,"fiveDayClose":33.2386,"twentyDayClose":33.1713,"sixtyDayClose":31.137},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CAMX\",params:#limit:5,,,undefined,":[{"date":"2025-12-30","symbol":"CAMX","amount":0.4793,"announcedDate":"2025-12-29","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-30","defaultRemindTime":1767105000000,"name":"Cambiar Aggressive Value ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-01-07","payableDate":"2025-12-30","currency":"USD","dateTimestamp":1767070800000,"payDate":"2026-01-07"},{"date":"2025-09-25","symbol":"CAMX","amount":0.0914,"announcedDate":"2025-09-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-25","defaultRemindTime":1758807000000,"name":"Cambiar Aggressive Value ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-26","payableDate":"2025-09-25","currency":"USD","dateTimestamp":1758772800000,"payDate":"2025-09-26"},{"date":"2024-12-30","symbol":"CAMX","amount":0.3884,"announcedDate":"2024-12-27","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-30","defaultRemindTime":1735569000000,"name":"Cambiar Aggressive Value ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-01-07","payableDate":"2024-12-30","currency":"USD","dateTimestamp":1735534800000,"payDate":"2025-01-07"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CAMX\",market:\"US\",,,undefined,":[{"executeDate":"2024-12-30","recordDate":"2024-12-30","paymentDate":"2025-01-07","value":0.3884,"currency":"USD"},{"executeDate":"2025-09-25","recordDate":"2025-09-25","paymentDate":"2025-09-26","value":0.0914,"currency":"USD"},{"executeDate":"2025-12-30","recordDate":"2025-12-30","paymentDate":"2026-01-07","value":0.4793,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CAMX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CAMX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2530615372","title":"Camurus Receives CHMP Recommendation for Potential Drug to Treat Rare Disease Caused by Pituitary Gland Tumor","url":"https://stock-news.laohu8.com/highlight/detail?id=2530615372","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530615372?lang=en_us&edition=fundamental","pubTime":"2025-04-25 23:08","pubTimestamp":1745593680,"startTime":"0","endTime":"0","summary":"Camurus  said Friday the European Medicines Agency's Committee for Medicinal Products for Human Use recommended the approval of Oczyesa to treat patients with acromegaly, a disease stemming from the pituitary gland.CHMP's positive opinion is backed by seven clinical trials of the potential drug, which showcased a \"higher proportion\" of patients who responded to treatment with somatostatin analogues, achieving normalized insulin growth-factor-1 levels versus placebo groups, the company said.One of the studies also showed improvement in symptoms and quality of life, according to a statement.The company said a final decision on the market authorization is expected from the European Commission mid-year.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4087","CHMP","CAMX"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":1,"code":"91000000","status":"200"}]}}